Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways

Human Molecular Genetics

Volumn 14, Issue SUPPL. 2, 2005, Pages

  Kwiatkowski, David J ^a   Manning, Brendan D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATE; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAPAMYCIN; TUBERIN;

CELL GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DROSOPHILA; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HAMARTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

CELL PROLIFERATION; CELL SIZE; GTPASE-ACTIVATING PROTEINS; HAMARTOMA; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA; RAPTORES;

EID: 27744588780     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddi260     Document Type: Review

References (97)

1. Gomez, M., Sampson, J. and Whittemore, V. (eds) (1999) The Tuberous Sclerosis Complex, 3rd edn. Oxford University Press, Oxford, England.
2. Curatolo, P. (2003) Tuberous Sclerosis Complex: Ftom Basic Science to Clinical Phenotypes. Mac Keith Press, Cambridge.
3. Roach, E.S., Gomez, M.R. and Northrup, H. (1998) Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J. Child Neurol., 13, 624-628.
4. Al-Saleem, T., Wessner, L.L., Scheithauer, B.W., Patterson, K., Roach, E.S., Dreyer, S.J., Fujikawa, K., Bjornsson, J., Bernstein, J. and Henske, E.P. (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer, 83, 2208-2216.
5. Crino, P.B. (2004) Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J. Child Neurol., 19, 716-725.
6. DiMario, F.J., Jr. (2004) Brain abnormalities in tuberous sclerosis complex. J. Child Neurol., 19, 650-657.
7. Goodman, M., Lamm, S.H., Engel, A., Shepherd, C.W., Houser, O.W. and Gomez, M.R. (1997) Cortical tuber count: A biomarker indicating neurologic severity of tuberous sclerosis complex. J. Child Neurol., 12, 85-90.
8. Shepherd, C.W., Houser, O.W. and Gomez, M.R. (1995) MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. Am. J. Neuroradiol., 16, 149-155.
9. Prather, P. and de Vries, P.J. (2004) Behavioral and cognitive aspects of tuberous sclerosis complex. J. Child Neurol., 19, 666-674.
10. Webb, D.W., Clarke, A., Fryer, A. and Osborne, J.P. (1996) The cutaneous features of tuberous sclerosis: A population study. Br. J. Dermatol., 135, 1-5.
11. Ewalt, D.H., Sheffield, E., Sparagana, S.P., Delgado, M.R. and Roach, E.S. (1998) Renal lesion growth in children with tuberous sclerosis complex. J. Urol., 160, 141-145.
12. Moss, J., Avila, N.A., Barnes, P.M., Litzenberger, R.A., Bechtle, J., Brooks, P.G., Hedin, C.J., Hunsberger, S. and Kristof, A.S. (2001) Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am. J. Respir. Crit. Care Med., 164, 669-671.
13. Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., Valeyre, D. and Cordier, J.F. (1999) Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires (GERM'O'P). Medicine (Baltimore), 78, 321-337.
14. Cheadle, J.P., Reeve, M.P., Sampson, J.R. and Kwiatkowski, D.J. (2000) Molecular genetic advances in tuberous sclerosis. Hum. Genet., 107, 97-114.
15. Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C. et al. (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet., 68, 64-80.
16. Jones, A.C., Shyamsundar, M.M., Thomas, M.W., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, J.R. and Cheadle, J.P. (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet., 64, 1305-1315.
17. Sancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D. and van den Ouweland, A. (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet., 13, 731-741.
18. O'Connor, S.E., Kwiatkowski, D.J., Roberts, P.S., Wollmann, R.L. and Huttenlocher, P.R. (2003) A family with seizures and minor features of tuberous sclerosis and a novel TSC2 mutation. Neurology, 61, 409-412.
19. Khare, L., Strizheva, G.D., Bailey, J.N., Au, K.S., Northrup, H., Smith, M., Smalley, S.L. and Henske, E.P. (2001) A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J. Med. Genet., 38, 347-349.
20. Au, K.S., Hebert, A.A., Roach, E.S. and Northrup, H. (1999) Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am. J. Hum. Genet., 65, 1790-1795.
21. Carbonara, C., Longa, L., Grosso, E., Mazzucco, G., Borrone, C., Garre, M.L., Brisigotti, M., Filippi, G., Scabar, A., Giannotti, A. et al. (1996) Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer, 15, 18-25.
22. Green, A.J., Smith, M. and Yates, J.R. (1994) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat. Genet., 6, 193-196.
23. Henske, E.P., Scheithauer, B.W., Short, M.P., Wollmann, R., Nahmias, J., Hornigold, N., van Slegtenhorst, M., Welsh, C.T. and Kwiatkowski, D.J. (1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet., 59, 400-406.
24. Niida, Y., Stemmer-Rachamimov, A.O., Logrip, M., Tapon, D., Perez, R., Kwiatkowski, D.J., Sims, K., MacCollin, M., Louis, D.N. and Ramesh, V. (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet., 69, 493-503.
25. Tucker, T. and Friedman, J.M. (2002) Pathogenesis of hereditary tumors: beyond the 'two-hit' hypothesis. Clin. Genet., 62, 345-357.
26. Han, S., Santos, T.M., Puga, A., Roy, J., Thiele, E.A., McCollin, M., Stemmer-Rachamimov, A. and Ramesh, V. (2004) Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res., 64, 812-816.
27. Chan, J.A., Zhang, H., Roberts, P.S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K. and Kwiatkowski, D.J. (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropath. Exp. Neurol., 63, 1236-1242.
28. The European Chromosome 16 Tuberous Sclerosis Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell, 75, 1305-1315.
29. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805-808.
30. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J., Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley, D. and van der Sluijs, P. (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet., 7, 1053-1058.
31. Plank, T.L., Yeung, R.S. and Henske, E.P. (1998) Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res., 58, 4766-4770.
32. Gao, X. and Pan, D. (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev., 15, 1383-1392.
33. Potter, C.J., Huang, H. and Xu, T. (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell, 105, 357-368.
34. Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E. and Hariharan, I.K. (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell, 105, 345-355.
35. Fingar, D.C. and Blenis, J. (2004) Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 23, 3151-3171.
36. Nobukini, T. and Thomas, G. (2004) The mTOR/S6K signalling pathway: The role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found. Symp., 262, 148-154.
37. Pan, D., Dong, J., Zhang, Y. and Gao, X. (2004) Tuberous sclerosis complex: From Drosophila to human disease. Trends Cell Biol., 14, 78-85.
38. Findlay, G.M., Harrington, L.S. and Lamb, R.F. (2005) TSC1-2 tumour suppressor and regulation of mTOR signalling: Linking cell growth and proliferation? Curr. Opin. Genet. Dev., 15, 69-76.
39. Hardie, D.G. (2005) New roles for the LKB1→AMPK pathway. Curr. Opin. Cell Biol., 17, 167-173.
40. Inoki, K., Corradetti, M.N. and Guan, K.L. (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet., 37, 19-24.
41. Inoki, K., Ouyang, H., Li, Y. and Guan, K.L. (2005) Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev., 69, 79-100.
42. Manning, B.D. (2004) Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell Biol., 167, 399-403.
43. Vanhaesebroeck, B. and Alessi, D.R. (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J., 346, 561-576.
44. Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
45. Alessi, D.R., Deak, M., Casamayor, A., Caudwell, F.B., Morrice, N., Norman, D.G., Gaffney, P., Reese, C.B., MacDougall, C.N., Harbison, D. et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol., 7, 776-789.
46. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol., 15, 177-182.
47. Manning, B.D. and Cantley, L.C. (2003) United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/ Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans., 31, 573-578.
48. Saucedo, L.J., Gao, X., Chiarelli, D.A., Li, L., Pan, D. and Edgar, B.A. (2003) Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol., 5, 566-571.
49. Stocker, H., Radimerski, T., Schindelholz, B., Wittwer, F., Belawat, P., Daram, P., Breuer, S., Thomas, G. and Hafen, E. (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol., 5, 559-565.
50. Zhang, Y., Gao, X., Saucedo, L.J., Ru, B., Edgar, B.A. and Pan, D. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol., 5, 578-581.
51. Garami, A., Zwartkruis, F.J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S.C., Hafen, E., Bos, J.L. and Thomas, G. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 11, 1457-1466.
52. Inoki, K., Li, Y., Xu, T. and Guan, K.L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev., 17, 1829-1834.
53. Dan, H.C., Sun, M., Yang, L., Feldman, R.I., Sui, X.M., Yeung, R.S., Halley, D.J., Nicosia, S.V., Pledger, W.J. and Cheng, J.Q. (2002) PI3K/ AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem., 277, 35364-35370.
54. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4, 648-657.
55. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. and Cantley, L.C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell, 10, 151-162.
56. Potter, C.J., Pedraza, L.G. and Xu, T. (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol., 4, 658-665.
57. Im, E., von Lintig, F.C., Chen, J., Zhuang, S., Qui, W., Chowdhury, S., Worley, P.F., Boss, G.R. and Pilz, R.B. (2002) Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene, 21, 6356-6365.
58. Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. and Blenis, J. (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol., 13, 1259-1268.
59. Castro, A.F., Rebhun, J.F., Clark, G.J. and Quilliam, L.A. (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem., 278, 32493-32496.
60. Martin, D.E. and Hall, M.N. (2005) The expanding TOR signaling network. Curr. Opin. Cell Biol., 17, 158-166.
61. Tee, A.R. and Blenis, J. (2005) mTOR, translational control and human disease. Semin. Cell Dev. Biol., 16, 29-37.
62. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M.N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell, 10, 457-468.
63. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110, 177-189.
64. Kim, D.H., Sarbassov dos, D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110, 163-175.
65. Kim, D.H., Sarbassov dos, D., Ali, S.M., Latek, R.R., Guntur, K.V., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 11, 895-904.
66. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 14, 1296-1302.
67. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A. and Hall, M.N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 6, 1122-1128.
68. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. and Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. Curr. Biol., 15, 702-713.
69. Hara, K., Yonezawa, K., Weng, Q.P., Kozlowski, M.T., Belham, C. and Avruch, J. (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem., 273, 14484-14494.
70. Smith, E.M., Finn, S.G., Tee, A.R., Browne, G.J. and Proud, C.G. (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem., 280, 18717-18727.
71. Richardson, C.J., Broenstrup, M., Fingar, D.C., Julich, K., Ballif, B.A., Gygi, S. and Blenis, J. (2004) SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol., 14, 1540-1549.
72. Raught, B., Peiretti, F., Gingras, A.C., Livingstone, M., Shahbazian, D., Mayeur, G.L., Polakiewicz, R.D., Sonenberg, N. and Hershey, J.W. (2004) Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J., 23, 1761-1769.
73. Lazaris-Karatzas, A., Montine, K.S. and Sonenberg, N. (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature, 345, 544-547.
74. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J. and Lowe, S.W. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 428, 332-337.
75. Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., Alessi, D.R. and Hardie, D.G. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2, 28.
76. Shaw, R.J., Kosmatka, M., Bardeesy, N., Hurley, R.L., Witters, L.A., DePinho, R.A. and Cantley, L.C. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA, 101, 3329-3335.
77. Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D., Schlatwer, U., Wallimann, T., Carlson, M. and Carling, D. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol., 13, 2004-2008.
78. Inoki, K., Zhu, T. and Guan, K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
79. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A. and Cantley, L.C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
80. Corradetti, M.N., Inoki, K., Bardeesy, N., DePinho, R.A. and Guan, K.L. (2004) Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev., 18, 1533-1538.
81. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P. and Blenis, J. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl Acad. Sci. USA, 101, 13489-13494.
82. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. and Pandolfi, P.P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell, 121, 179-193.
83. Ballif, B.A., Roux, P.P., Gerber, S.A., MacKeigan, J.P., Blenis, J. and Gygi, S.P. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl Acad. Sci. USA, 102, 667-672.
84. Astrinidis, A., Senapedis, W., Coleman, T.R. and Henske, E.P. (2003) Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem., 278, 51372-51379.
85. Reiling, J.H. and Hafen, E. (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev., 18, 2879-2892.
86. Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Witters, L.A., Ellisen, L.W. and Kaelin, W.G., Jr. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/ TSC2 tumor suppressor complex. Genes Dev., 18, 2893-2904.
87. Zhang, H., Cicchetti, G., Onda, H., Koon, H.B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C.L. and Kwiatkowski, D.J. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest., 112, 1223-1233.
88. Nellist, M., Sancak, O., Goedbloed, M.A., Rohe, C., van Netten, D., Mayer, K., Tucker-Williams, A., van den Ouweland, A.M. and Halley, D.J. (2005) Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur. J. Hum. Genet., 13, 59-68.
89. El-Hashemite, N., Zhang, H., Henske, E.P. and Kwiatkowski, D.J. (2003) Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet, 361, 1348-1349.
90. Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S., Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski, D.J., Chou, M.M. et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem., 277, 30958-30967.
91. Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G. and Lamb, R. (2002) Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol., 159, 217-224.
92. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M., el-Hashemite, N. and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11, 525-534.
93. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R. et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol., 166, 213-223.
94. Shah, O.J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol., 14, 1650-1656.
95. Manning, B.D., Logsdon, M.N., Lipovsky, A., Abbott, D., Kwiatkowski, D.J. and Cantley, L.C. (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev., in press.
96. Kenerson, H., Dundon, T.A. and Yeung, R.S. (2004) Effects of rapamycin in the eker rat model of tuberous sclerosis complex. Pediatr. Res., 57, 67-75.
97. Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M.S., El-Hashemite, N. et al. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer, 42, 213-227.